Paul Berns

Jazz Pharmaceuticals, Inc. develops and markets pharmaceutical products. Its medical products include xyrem, erwinaze, vyxeos, and kidrolas. The company was founded by Bruce C. Cozadd in 2003 and is headquartered in Palo Alto, CA.

Ren Pharmaceuticals was formed in the fall of 2006 with the aim of bringing together talented and experienced people who are passionate about building a cardio-renal/renal- focused drug development company. Ren Pharmaceuticals closed a Series A financing in November 2006 with Sanderling Ventures, Venrock Associates and Amgen Ventures as investors. The company's R&D is currently located in South San Francisco, California.

Epirium Bio, Inc. develops therapeutics for orphan and rare diseases characterized by impairment of the skeletal muscle, cardiac and neuronal systems. The company was founded in 2008 by Alan Stewart Maisel, Sundeep Dugar, and Francisco Villarreal and is headquartered in Los Altos Hills, CA.

Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA.

Part of BASF SE, Knoll AG develops pharmaceuticals. The private company is based in Haren, Germany.

XenoPort, Inc. operated as a biopharmaceutical company. Its products included horizant and regnite. The company was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on December 17, 1999 and was headquartered in Atlanta, GA.

Part of BASF SE, BASF SA is a Brazilian company that manufactures chemicals, paints, agricultural products and others. The private company is based in São Paulo, Brazil.

Novelos Therapeutics, Inc. is a pharmaceutical company, which is engaged in the development of novel drugs for the treatment and diagnosis of cancer. It comprises of three cancer-targeted compounds: GLOW2, HOT and LIGHT, which are used for the treatment of cancer. Its therapeutic compounds directly kill cancer cells while minimizing harm to normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy in all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. Its LIGHT compound is a small-molecule cancer-targeted imaging agent, which is potential for selective detection of tumors and metastases in a broad range of cancers. Its HOT compound is a small-molecule, broad-spectrum, cancer-targeted molecular radio therapeutic that delivers radiation directly and selectively to cancer cells and cancer stem cells. Its GLOW2 compound is a small-molecule, broad-spectrum, cancer-targeted, non-radioactive optical imaging agent which is potential for intraoperative tumor margin illumination and non-invasive tumor imaging. The company was founded on June 21, 1996 and is headquartered in Madison, WI.

Anacor Pharmaceuticals, Inc. develops medical solutions. The firm operates as a biopharmaceutical company, which focuses on discovering, developing, and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. The company was founded by Lucy Shapiro, Stephen J. Benkovic, and David P. Perry in 2000 and is headquartered in Palo Alto, CA.

Blackthorn Therapeutics, Inc. manufactures and markets medicines for neuro developmental disorders. The company is headquartered in San Francisco, CA.

Mc2 Therapeutics is a Danish commercial stage biotech company that focuses on developing novel treatment paradigms for immune-mediated and inflammatory diseases. Mc2 Therapeutics is based in Denmark, specifically in Hørsholm, and has subsidiaries in the United Kingdom. The company is privately held and is developing a new standard of topical therapies for chronic inflammatory conditions using PAD™ technology. The company aims to release the full potential of novel topical drugs for the benefit of patients, physicians, payers, and societies.

EQRx International, Inc. engages in healthcare services. The firm specializes in remaking medicine services. The company was founded by Peter Bach and Sandra Horning on January 12, 2020 and is headquartered in Cambridge, MA.

RBNC Therapeutics, Inc. develops and commercializes therapies for individuals with brain diseases.

Happy Health, Inc. is a mission-driven technology company founded in 2019 and based in - that is committed to transforming mental health awareness. The company is based in Austin, TX and has subsidiaries in the United States. The company has developed the Happy Ring, which is the first wearable for your mind. The Happy Ring measures your stress and mood 24/7, providing real-time mood tracking that can change your life.

HIBio, Inc. is a clinical immunology company that leverages human genetic and immunological insights to deliver targeted therapies to patients with severe immune-mediated diseases. The company is based in South San Francisco, CA. HIBio is excited to work as part of a collaborative team. HIBio was founded by Tim Behrens and Travis Murdoch, with Travis Murdoch serving as the CEO since incorporation.

Elephas Biosciences Corp. is a live tumor imaging company that provides cancer diagnostic solutions to predict treatment outcomes and accelerate drug development. The company is based in Madison, WI and was founded by Maneesh K. Arora, who has been the CEO since incorporation. The company's revolutionary diagnostic platform brings insights to cancer treatment decisions and accelerates immuno-oncology drug development. Investors can learn about clinical trials aimed at predicting responses to immunotherapy and how immunotherapeutic drug development can be accelerated with Elephas Biosciences's cybrid.

Areteia Therapeutics, Inc. is a clinical stage biotechnology company that focuses on developing and delivering novel inflammation and immunology therapies for respiratory patients. The company is based in Short Hills, NJ, and the CEO of the company is Jorge Bartolome. The company's initial focus is on developing the first potential oral drug for eosinophilic asthma, with its lead drug candidate being dexpramipexole, a first-in-class oral eosinophil maturation inhibitor. Areteia was created by Population Health Partners and Knopp Biosciences, and a syndicate of leading life sciences and strategic investors has committed to investing up to $350 million in series A financing to establish Areteia and advance dexpramipexole through phase III clinical trials.

Human Immunology Biosciences, Inc. is a company based in South San Francisco, CA. Human Immunology Biosciences, Inc. was founded by Travis Murdoch, who has been the CEO since incorporation.